Esperion Therapeutics (ESPR) Current Deferred Revenue (2019 - 2026)

Esperion Therapeutics has reported Current Deferred Revenue for 8 years, with the latest figure at $43.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 858.41% year-over-year to $43.5 million; the trailing twelve-month figure through Mar 2026 stood at $43.5 million (up 858.41% YoY), and the FY2025 full-year result was $34.5 million, up 304.75% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $43.5 million, up from $34.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $43.5 million in Q1 2026, with the low at $3.5 million in Q4 2022.
• Historically, Current Deferred Revenue has averaged $17.6 million across 5 years, with a median of $15.6 million in 2023.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue sank 84.52% — and 2026, when it surged 858.41%.
• Esperion Therapeutics' Current Deferred Revenue stood at $3.5 million in 2022, then surged by 624.32% to $25.4 million in 2023, then sank by 66.47% to $8.5 million in 2024, then surged by 304.75% to $34.5 million in 2025, then grew by 26.26% to $43.5 million in 2026.
• The last three Current Deferred Revenue figures came in at $43.5 million (Q1 2026), $34.5 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.